For the fiscal year ending June 2026, consolidated net sales were 387.1 million yen, operating income was 275 million yen, and net income attributable to owners of the parent was 212 million yen. Full-year guidance is net sales of 3,270 million yen, operating income of 300 million yen, and net income attributable to owners of the parent of 250 million yen. In August 2026, the company plans to reorganize its businesses including a healthcare platform, aiming for growth in the next segment. The dividend is expected to be 10 yen per share for the year.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2385","jir_company_name":"Total Medical Research Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/2385-20260812-01.pdf","jir_short_summary":"For the fiscal year ending June 2026, consolidated net sales were 387.1 million yen, operating income was 275 million yen, and net income attributable to owners of the parent was 212 million yen. Full-year guidance is net sales of 3,270 million yen, operating income of 300 million yen, and net income attributable to owners of the parent of 250 million yen. In August 2026, the company plans to reorganize its businesses including a healthcare platform, aiming for growth in the next segment. The dividend is expected to be 10 yen per share for the year.","jir_summary":"### Overview of Business Performance\nThis fiscal year, consolidated net sales were 3,871 million yen, operating income 275 million yen, and net income attributable to owners of the parent 212 million yen. By segment, contributions came from Biometric Evaluation Systems, Healthcare Support, Cosmetics, Health Supplements, and Functional Materials Development. Overall, net sales declined versus the previous year. The financial results summary notes a restructuring as part of a portfolio overhaul, including retreat from the Chinese market and organizational integration. For the next year, the company will focus on the Healthcare Platform business and strengthen domestic and international expansion.\n\n### Outlook and Dividend Policy\nFor the next fiscal year (the year ending June 2027), consolidated projections are net sales of 3,270 million yen, operating income of 300 million yen, ordinary income of 310 million yen, and net income attributable to owners of the parent of 250 million yen. The company plans to build a comprehensive healthcare platform powered by medical DX, with expanded domestic and international deployment. In terms of shareholder returns, a year-end dividend of 10 yen per share is planned, with an annual dividend of 10 yen expected for the next year as well.","jir_financial_highlights":"Net sales: 3,871\u767e\u4e07\u5186 (YoY -20.2%)\nOperating income: 275\u767e\u4e07\u5186 (YoY turned to positive (previous year was a loss of \u25b3137\u767e\u4e07\u5186))\nNet income attributable to owners of the parent: 212\u767e\u4e07\u5186 (From a loss of \u25b3210\u767e\u4e07\u5186 YoY to profit)\nNext term net sales forecast: 3,270\u767e\u4e07\u5186 (Forecast)\nNext term operating income forecast: 300\u767e\u4e07\u5186 (Forecast)","jir_category":"","jir_hashtags":"#\u7dcf\u533b\u7814, #\u6c7a\u7b97, #\u30d8\u30eb\u30b9\u30b1\u30a2\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0, #\u4e8b\u696d\u518d\u7de8, #\u914d\u5f53\u65b9\u91dd","jir_key_figures":"Net sales: 3,871\u767e\u4e07\u5186 (YoY -20.2%)\nOperating income: 275\u767e\u4e07\u5186 (YoY previously a loss of 137\u767e\u4e07\u5186)\nNet income attributable to owners of the parent: 212\u767e\u4e07\u5186 (YoY from a loss of 210\u767e\u4e07\u5186)","jir_meta_title":"Total Medical Research Holdings \u2013 June 2026 Financial Results | Net Sales 3,871 million yen, Next Year to Build Healthcare Platform","jir_meta_description":"Overview of Total Medical Research Holdings' June 2026 financial results. Net sales 3,871 million yen, operating income 275 million yen, net income 212 million yen. Includes restructuring, full-scale healthcare platform deployment, next-year forecasts, and dividend policy.","jir_og_title":"Total Medical Research Holdings Announces June 2026 Quarterly Results","jir_og_description":"Overview of the company\u2019s results: net sales 3,871 million yen, operating income 275 million yen, with plans to expand the healthcare platform and maintain stable dividends next year.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59673,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-102403","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n